Droolingking
2021-06-14
Good
Moderna Inks Partnership Deal with Tabuk Pharmaceuticals
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":185769771,"tweetId":"185769771","gmtCreate":1623673993193,"gmtModify":1634030286246,"author":{"id":3585981723267031,"idStr":"3585981723267031","authorId":3585981723267031,"authorIdStr":"3585981723267031","name":"Droolingking","avatar":"https://static.tigerbbs.com/0725572fa8101e15839f715f0b5e9e53","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/185769771","repostId":2143781157,"repostType":4,"repost":{"id":"2143781157","kind":"news","pubTimestamp":1623660416,"share":"https://www.laohu8.com/m/news/2143781157?lang=&edition=full","pubTime":"2021-06-14 16:46","market":"us","language":"en","title":"Moderna Inks Partnership Deal with Tabuk Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2143781157","media":"SmarterAnalyst","summary":"The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharma","content":"<p>The pharmaceutical and biotechnology company <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> (<b>MRNA</b>) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session.</p>\n<p>The financial terms of the deal have not been disclosed.</p>\n<p>Per the agreement, Tabuk could get the opportunity to distribute other authorized Moderna mRNA products in the future.</p>\n<p>Tabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, is a Saudi pharmaceuticals company.</p>\n<p>Moderna CEO Stephane Bancel said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia.”</p>\n<p>Bancel further added, “It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.” (See Moderna stock analysis on TipRanks)</p>\n<p>On June 10, Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on the stock but increased the price target to $224 (2.4% upside potential) from $205.</p>\n<p>Cann commented, “For a company at Moderna’s stage of development, which is largely pre-approval, we primarily focus on potential future revenue to value the company. Based on our expectation that in addition to its already launched COVID-19 vaccine, Moderna will launch several of its development-stage products in the next six years, we estimate that Moderna’s total revenue will increase to $100.1 billion in 2030.”</p>\n<p>The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 6 Buys, 3 Holds, and 2 Sells. The MRNA average analyst price target of $194 implies 11.4% downside potential to current levels. Shares have increased 41.1% over the past six months.</p>\n<p><img src=\"https://static.tigerbbs.com/a7b9b1c14597ff8c93148627f4cdbe23\" tg-width=\"825\" tg-height=\"286\" referrerpolicy=\"no-referrer\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Inks Partnership Deal with Tabuk Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Inks Partnership Deal with Tabuk Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 16:46 GMT+8 <a href=https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html><strong>SmarterAnalyst</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-inks-partnership-deal-tabuk-074356756.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143781157","content_text":"The pharmaceutical and biotechnology company Moderna, Inc. (MRNA) has collaborated with Tabuk Pharmaceuticals to market its COVID-19 Vaccine and future, variant-specific booster candidates, in Saudi Arabia. Shares of the company declined 1.3% in Friday’s extended trading session.\nThe financial terms of the deal have not been disclosed.\nPer the agreement, Tabuk could get the opportunity to distribute other authorized Moderna mRNA products in the future.\nTabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, is a Saudi pharmaceuticals company.\nModerna CEO Stephane Bancel said, “We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia.”\nBancel further added, “It is thanks to partnerships such as these that we are able to expand access to our vaccine globally, and we hope it will support the availability of our COVID-19 vaccine for the benefit of the people of Saudi Arabia.” (See Moderna stock analysis on TipRanks)\nOn June 10, Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on the stock but increased the price target to $224 (2.4% upside potential) from $205.\nCann commented, “For a company at Moderna’s stage of development, which is largely pre-approval, we primarily focus on potential future revenue to value the company. Based on our expectation that in addition to its already launched COVID-19 vaccine, Moderna will launch several of its development-stage products in the next six years, we estimate that Moderna’s total revenue will increase to $100.1 billion in 2030.”\nThe rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 6 Buys, 3 Holds, and 2 Sells. The MRNA average analyst price target of $194 implies 11.4% downside potential to current levels. Shares have increased 41.1% over the past six months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/185769771"}
精彩评论